Study of a three-drug combination for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of three drugs (belantamab mafodotin, cevostamab, and pomalidomide) for patients with multiple myeloma that has returned or stopped responding to previous treatments. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and willing to sign a consent form.
- You must have a diagnosis of multiple myeloma that has come back after treatment (relapsed) and, for some parts, did not respond to the last treatment (refractory).
- You should have received at least one prior treatment, including common myeloma drugs like lenalidomide, a proteasome inhibitor (e.g., bortezomib), or an anti-CD38 antibody (e.g., daratumumab).
- The disease must be 'measurable' – meaning there are clear signs of it in your blood or urine that can be tracked.
- If you've had a stem cell transplant using your own cells, it must have been more than 100 days ago.
- You must be in reasonably good general health (able to care for yourself, up and about) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, elranatamab and isatuximab, given together to people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if the combination can shrink or control the cancer where other therapies have not worked well.
This trial tests whether REGN17372 plus linvoseltamab is safe for people with multiple myeloma that has come back or not responded to prior treatments. You may join if you have tried at least 3 other therapies.
This trial tests a new way of giving a combination of three drugs—belantamab mafodotin, bortezomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if a different dosing schedule is more effective and safer.
This trial tests a new combination of drugs for people with multiple myeloma that has come back after previous treatment. The goal is to see if adding belantamab mafodotin to standard drugs can help control the disease better.
This trial tests whether a new drug called cevostamab, combined with two existing myeloma drugs (pomalidomide and dexamethasone), works better than standard treatment for people whose myeloma has returned or stopped responding to prior therapy. You would receive this combination to see if it helps control your disease.
This study tests a new combination of drugs for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if the combination helps control the disease.
Hear when a new Relapsed Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.